Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC 3Q11 Trend Analysis, now available
    - OnBioVC 4Q11 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • FDA Registered Contract Manufacturer

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

CircuLite (Saddle Brook, NJ) a clinical-stage medical device company focused on minimally invasive implantable devices for chronic heart failure, closed a $30M Series D financing. Participants include Forbion Capital Partners and MacAndrews & Forbes Holdings.

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Provenance Biopharmaceuticals (Waltham, MA) a clinical-stage biopharmaceutical company focused on monoclonal antibody therapy for non-Hodgkins lymphoma and other hematological cancers, closed a $8M Series A financing. Participants include Alopexx Enterprises.

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Cerulean Pharma (Cambridge, MA) a clinical-stage nanopharmaceutical company focused on non-small cell lung cancer, closed a $15M Series D financing. Participants include Lilly Ventures, Polaris Venture Partners, Venrock, Lux Capital, CVF and Bessemer Venture Partners.

Innopharma (Piscataway, NJ) a development-stage specialty pharmaceutical company focused on generics and drug delivery technology platforms for existing drugs, closed a $15M Series A financing. Participants include Thomas, McNerney & Partners.

Karyopharm Therapeutics (Natick, MA) a preclinical-stage small molecule company focusing on the treatment of cancer and inflammation, closed a $10M Series A financing, bringing the total round to $30M. Participants include Chione.

PathoGenetix (Woburn, MA) a development-stage sequencing company focused on simultaneous identification and characterization of bacterial strains in a single test, closed a $7.5M Series B financing, bringing the total round to $11.5M. Participants include Ascension Health Ventures, Excel Venture Management, CB Health Ventures and HealthCare Ventures.

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures.
Thanx for your patience as we catch-up.

NABsys (Providence, RI) a development stage dna sequencing company focused on nanopore arrays that can do not require amplification or labeling, closed a $10M Series C financing. Participants include Stata Venture.
Thanx for your patience as we catch-up.

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.
Thanx for your patience as we catch-up.

« Previous Entries  

to top of page...